Joshua Reuss, MD| Thoracic Medical Oncology, Medical Oncology | MedStar Health
Joshua Reuss

Joshua Reuss, MD
Provider is directly employed by MedStar Health

4.9 out of 5 (107 reviews)

Specialties: Thoracic Medical Oncology, Medical Oncology

Languages: English

About me

Joshua Reuss, MD, is a thoracic medical oncologist at MedStar Georgetown University Hospital. He also serves as an assistant professor in the Department of Medicine at Georgetown University Medical Center.

Dr. Reuss specializes in lung cancer, mesothelioma, and thymoma. His research focuses on incorporating novel concepts and groundbreaking science to develop innovative clinical trials that advance the care of patients with lung cancer and mesothelioma. He has a particular interest in collaborating with scientific investigators to develop studies that help improve our understanding of the response and resistance mechanisms to immunotherapy in lung cancer and mesothelioma, as well as to develop trials that incorporate novel therapies that overcome immunotherapy resistance. He received the Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology in 2019 for his research.

Dr. Reuss earned his bachelor’s degree in biology at Brandeis University and his MD from the University of Rochester School of Medicine & Dentistry. He completed his internship and residency in Internal Medicine at the University of Virginia’s Department of Medicine. He subsequently completed a fellowship in the Department of Oncology at the Johns Hopkins University School of Medicine.

MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, the Georgetown Lombardi Comprehensive Cancer Center, is the only National Cancer Institute-designated comprehensive cancer center in the Washington, D.C., region. This partnership means we provide access to cutting-edge clinical trials and the latest breakthroughs in cancer care.

Clinical areas of focus

  • Adenocarcinoma Of Lung
  • Lung Cancer
  • Lung Metastasis
  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Pulmonary Nodule
  • Small Cell Lung Cancer
  • Thymoma
  • Thymus Cancer
Show More

Conditions and procedures

Conditions I treat

  • Adenocarcinoma Of Lung
  • Alk Translocation
  • Asbestos Lung
  • Chest Wall Tumors
  • Egfr Mutation
  • Inherited Lung Cancer Risk
  • Kras Mutation
  • Large Cell Cancer Of The Lung
  • Lung Cancer
  • Lung Metastasis
  • Mediastinum Cancer
  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Pleural Cancer
  • Pulmonary Carcinoid
  • Pulmonary Nodule
  • Ros1 Fusion
  • Small Cell Lung Cancer
  • Squamous Cancer Of The Lung
  • Thoracic Malignancy
  • Thymoma
  • Thymus Cancer
Show All Show Less

Procedures I perform

  • Cancer Immunotherapy
  • Lung Cancer Genomics
Show All button Press enter to expand Show Less

Practice locations

Distance from Change LocationEnter your Location

3800 Reservoir Road Northwest
Lombardi Cancer Center
Washington, DC, 20007


Fax 202-444-1229

Get Directions

miles away

Fax 202-444-1229


MedStar Health accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Health, please call your insurance company.

  • List of insurance plans we accept
    • Aetna Open Choice (PPO)
    • Aetna Medicare Advantage HMO & PPO Plans
    • Innovation Health: Open POS Plus
    • Innovation Health: Open POS II
    • Aetna Managed Choice Open Access (POS)
    • Aetna Choice POS & Choice POS II
    • Innovation Health: POS Plus
    • Aetna Managed Choice (POS)
    • Innovation Health: POS
    • Aetna Open HMO/Open HMO Option/Open EPO Plus
    • Aetna HMO-Open Access/Select OA
    • Aetna HealthFund/Health Network Option OA
    • Innovation Health: HMO & EPO Plus
    • Aetna Select HMO/HealthFund/Health Network
    • Aetna HMO
    • Innovation Health: Open Network Only Plus
    • Aetna Elect Choice/ Open Access (POS)
    • Innovation Health: Network Only Plus
    • Aetna Elect Choice/ EPO (Aetna Health Fund)
    • Cigna TotalCare (HMO D-SNP)
    • Cigna Preferred Medicare
    • Cigna Alliance Medicare (HMO) |
    • Cigna Achieve Medicare (HMO C-SNP)
    • Veterans Affairs Community Care Network (VA CCN)
    • United Medicare Advantage DSNP District of Columbia
    • United Student Resources
    • United Select Plus (POS)
    • United Select HMO - EPO/NPP
    • United Options (PPO) (includes Empire PPO)
    • United Golden Rule
    • United GEHA (for all other states) Compass Rose
    • D-SNP)
    • I-SNP
    • United Nursing Home Plan (C-SNP
    • United Erickson Advantage Plans
    • United Choice Plus
    • United Choice
    • United Mamsi Life & Health
    • MedStar Family Choice DC Healthy Families
    • MedStar Family Choice DC Healthcare Alliance
    • United MD IPA Preferred (POS)
    • United MD IPA (HMO)
    • Kaiser Permanente Signature-Added Choice
    • Kaiser Signature
    • Kaiser HMO Plus and DHMO Plus Member
    • Kaiser Select-Added Choice
    • Kaiser Select
    • Kaiser Medicare Plus
    • Kaiser Medicare Advantage Signature and Select
    • Kaiser Flexible Choice
    • Kaiser Maryland Medicaid MCO
    • HumanaChoice PPO
    • HumanaChoice Honor’s plan PPO
    • Health Services for Children with Special Needs (HSCSN)
    • Cigna True Choice Plus Medicare (PPO)
    • Cigna True Choice Medicare (PPO)
    • Cigna POS/Network POS
    • Cigna Indemnity
    • Cigna POS Open Access & Open Access Plus
    • Cigna Network Open Access
    • Cigna HMO Open Access
    • Cigna PPO and PPO Plus
    • Cigna EPO
    • Cigna Choice Fund PPO
    • Choice Care Network/HUMANA (PPO)
    • Beech Street PPO
    • Anthem Plus BCBS of VA HealthKeepers Plus
    • Anthem (POS & Open Access POS) BCBS of VA HealthKeepers
    • Anthem HMO - BCBS of VA HealthKeepers
    • Innovation Health: Indemnity
    • Aetna Traditional Choice (PPO)
    • Aetna Student Health Insurance
    • Aetna Signature Administrator PPO/TPA
    • Aetna Quality Point of Service (POS)
    • Innovation Health: PPO
    • Cigna HMO & Network (HMO)
    • WellPoint Maryland - Maryland Health Choice
    • WellPoint Maryland
    • Virginia Premier
    • Veterans Affairs Community Care Network
    • UnitedHealthcare Individual Exchange Plans
    • United Community Plan - Maryland Health Choice Program
    • Private Health Care Systems (PHCS) (PPO)
    • Police and Fire Clinic
    • United Optimum Choice Preferred (POS) & OCI Direct (HMO)
    • United Optimum Choice
    • United Navigate
    • United Core Essential (HMO)
    • United Group Medicare Advantage Plans
    • United AARP Medicare Complete
    • Traditional Medicare Fee for Service
    • Medicaid - Virginia
    • Medicaid - Maryland
    • Medicaid - District of Columbia
    • Tricare for Life East
    • Tricare Reserve Select
    • Tricare East Select
    • Tricare East Prime
    • Maryland Point of Service Plan (MPOS)
    • HealthyBlue PPO
    • Federal Employee Program (Std/Basic PPO/Blue Focus)
    • CareFirst NASCO
    • CareFirst MedStar Select PPO
    • CareFirst MedStar PPO
    • CareFirst Maryland Indemnity or PPO
    • CareFirst Group Medicare Advantage prescription drug benefit (PPO)
    • CareFirst Group Medicare Advantage
    • CareFirst BC/BS Advantage Core/Enhanced
    • CareFirst Blue Card Program (Out-of-area BCBS plans)
    • CareFirst Administrators
    • CareFirst (NCA) Indemnity
    • Carefirst BlueChoice Opt Out Plus Open Access (POS)
    • Carefirst Healthy Blue (HMO/POS)
    • Carefirst BlueChoice Opt Out Open Access
    • Carefirst BlueChoice Open Access
    • Carefirst BlueChoice HMO
    • Carefirst EPO
    • Carefirst Blue Preferred PPO
    • Coventry of Delaware HMO/PPO
    • MedStar Family Choice - Maryland Health Choice
    • First Health PPO
    • Coventry Health Care National Network PPO
    • Coventry Health Care of Virginia
    • Great-West Healthcare POS/CIGNA



Board Certification: American Board of Internal Medicine, Internal Medicine

Board Certification: American Board of Internal Medicine, Medical Oncology

Fellowship Program: Johns Hopkins University School of Medicine (2020)

Residency Program: University of Virginia Health System (2017)

Medical School: University of Rochester School of Medicine (2014)


  • Research Award Recipient, 3rd Annual EGFR Resisters Research Summit, 2021
  • Selected Participant, Journal of Clinical Oncology – Precision Oncology Trainee Reviewer Mentoring Program, 2022
  • Selected Participant, FDA-ASCO Hematology and Oncology Fellows Day Workshop, 2019
  • Young Investigator Award, Conquer Cancer Foundation of ASCO, 2019
  • Visiting Fellow, Investigational Drug Branch - Cancer Therapy Evaluation Program of the NCI, 2019
  • Best Fellows Abstract Oral Presentation, IASLC Targeted Therapies of Lung Cancer Meeting, 2019
  • Selected Participant, ASCO/AACR Methods in Clinical Cancer Research Workshop, 2018

News and publications

i. Original Research

  1. Reuss JE, Brigham E, Psoter KJ, Voong KR, Shankar B, Ettinger DS, Marrone KA, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, Hales RK, D’Alessio F, Danoff SK, Forde PM, Suresh K, Naidoo J. Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. JTO Clin Res Rep. 2021 October 01; 2(10):100220. doi:
  2. Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH-C, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, Singh D, Thapa S, Dykema AG, Burman P, Choudhury B, Aparicio L, Cheung LS, Lanis M, Belcaid Z, El Asmar M, Illei PB, Wang R, Meyers J, Schuebel K, Gupta A, Skaist A, Wheelan S, Naidoo J, Marrone KA, Brock M, Ha J, Bush EL, Park BJ, Bott M, Jones DR, Reuss JE, Velculescu VE, Chaft JE, Kinzler KW, Zhou S, Vogelstein B, Taube JM, Hellmann MD, Brahmer JR, Mergoub T, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021;596(7870):126-132. doi: 10.1038/s41586-021-03752-4. PubMed PMID: 34608287; PubMed Central PMCID: PMC8338555.
  3. Reuss JE, Stern D, Foster JC, Ramaswami R, Lurain K, Chen HX, Streicher H, Kem R, Little RF, Sharon E. Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti-programmed death ligand 1 clinical trials. JAMA Netw Open. 2020 Dec 1;3(12):e2027110. doi: 10.1001/jamanetworkopen.2020.27110. PubMed PMID: 33258905; PubMed Central PMCID: PMC7709086.
  4. #Rahma OE, #Reuss JE, Giobbie-Hurder A, Razavi G-SE, Abu-Shawer O, Mehra P, Gupta S, Simon R, Khleif SN. Early 3+3 trial dose-escalation phase I clinical trial design and suitability for immune checkpoint inhibitors. Clin Cancer Res. 2020 Oct 20;clincanres.2669.2020. doi: 10.1158/1078-0432.CCR-20-2669. PubMed PMID: 33082209. #contributed equally.
  5. Reuss JE, Anangostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, Wang D, White JR, Yang S, Battafarano R, Broderick S, Bush E, Brock M, Ha J, Jones DR, Merghoub T, Taube J, Velculescu VE, Rosner G, Illei P, Pardoll DM, Topalian SL, Naidoo J, Levy B, Hellmann MD, Brahmer JR, Chaft JE, Forde PM. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020 Sep;8(2):e001282. doi: 10.1136/jitc-2020-001282. PubMed PMID: 32929052; PubMed Central PMCID: PMC7488786.
  6. Naidoo J, Reuss JE, Suresh K, Feller-Kopman D, Forde PM, Steinke SM, Rock C, Johnson DB, Nishino M, Brahmer JR. Immune-related (IR)-pneumonitis during the COVID-19 pandemic: Multidisciplinary recommendations for diagnosis and management. J Immunother Cancer. 2020 Jun;8(1):e000984. doi: 10.1136/jitc-2020-000984. PubMed PMID: 32554619; PubMed Central PMCID: PMC7316105.
  7. Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, Chan HY, Suri P, Guo H, Merghoub T, Chaft JE, Reuss JE, Tam AJ, Blosser RL, Abu-Akeel M, Sidhom JW, Zhao N, Ha JS, Jones DR, Marrone KA, Naidoo J, Gabrielson E, Taube JM, Velculescu VE, Brahmer JR, Housseau F, Hellmann MD, Forde PM, Pardoll DM, Ji H, Smith KN. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Clin Cancer Res. 2020 Mar 15;26(6):1327-1337. doi: 10.1158/1078-0432.CCR-19-2931. PubMed PMID: 31754049; PubMed Central PMCID: PMC7073288.
  8. Anagnostou V, Niknafs N, Marrone K, Bruhm DC, White JR, Naidoo J, Hummelink K, Monkhorst K, Lalezari F, Lanis M, Rosner S, Reuss JE, Smith KN, Adleff V, Rodgers K, Belcaid Z, Rhymee L, Levy B, Feliciano J, Hann CL, Ettinger DS, Georgiades C, Verde F, Illei P, Li QK, Baras AS, Gabrielson E, Brock MV, Karchin R, Pardoll DM, Baylin SB, Brahmer JR, Scharpf RB, Forde PM, Velculescu VE. Mulitmodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer. 2020 Jan 13;1:99-111. doi: 10.1038/s43018-019-0008-8. PubMed PMID: 32984843; PubMed Central PMCID: PMC7514475
  9. Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Immune-related adverse events requiring inpatient admission: spectrum of toxicity, treatment, and outcomes. J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. PubMed PMID: 31386608. PubMed Central PMCID: PMC6743220.
  10. Cavelti-Weder C, Shtessel M, Reuss JE, Jermendy A, Yamada T, Caballero F, Bonner-Weir S, Weir GC. Pancreatic duct ligation after almost complete beta-cell loss: Exocrine regeneration but no evidence of beta-cell regeneration. Endocrinology. 2013 May;154(12):4493-502. doi: 10.1210/en.2013-1463. PubMed PMID: 24029238; PubMed Central PMCID: PMC3836076.

ii. Reviews and Editorials

  1. Reuss JE, Gosa L, Liu SV. Antibody drug conjugates in lung cancer: State of the current therapeutic landscape and future developments. Clin Lung Ca. 2021 Jul;S1525-7304(21)00192-3. doi: 10.1016/j.cllc.2021.07.011. PubMed PMID: 34420859.
  2. *Reuss JE, *Forde PM. Immunotherapy for mesothelioma: rationale and new approaches. Clin Adv Hematol Oncol. 2020 Sep;18(9):562-572. PubMed PMID: 33006585.
  3. *Reuss JE, Suresh K, *Naidoo J. Checkpoint inhibitor pneumonitis: Mechanisms, characteristics, management strategies, and beyond. Curr Oncol Rep. 2020 May 16;22(6):56. doi: 10.1007/s11912-020-00920-z. PubMed PMID: 32415399.
  4. Jonna S, Reuss JE, Kim C, Liu SV. Oral chemotherapy for treatment of lung cancer. Front Oncol. 2020 Apr 28;10:793. doi: 10.3389/fonc.2020.00793. PubMed PMID: 32426292; PubMed Central PMCID: PMC7212352.
  5. Schenk KM, Reuss JE, Choquette K, Spira AI. A review of canakinumab and its therapeutic potential for non-small cell lung cancer. Anticancer Drugs. 2019 Oct;30(9):879-885. doi: 10.1097/CAD.0000000000000832. PubMed PMID: 31503012.
  6. #Rosner S, #Reuss JE, Forde PM. PD-1 Blockade in Early-Stage Lung Cancer. Annu Rev Med. 2019 Jan;70:425-35. doi: 10.1146/annurev-med-050217-025205. PubMed PMID: 30355264. #contributed equally.

Ratings and reviews

  • Explanations the care provider gave you about your problem or condition

  • Extent to which the care provider listened to you

  • Care provider’s discussion of any proposed treatment (options, risks, benefits, etc.)

  • Care provider’s efforts to include you in decisions about your care

  • Concern the care provider showed for your questions or worries

  • Likelihood of recommending this care provider to others

  • May 2, 2024

    I've been very pleased with the care provided by Dr Reuss and our relationship.

  • Apr 30, 2024


  • Mar 21, 2024

    As a new patient was very pleased with discussions with doctor. He listened carefully to my medical history. This was followed by discussion of my medical problem and potential treatment options.